Ventricular arrhythmias (within 30 days) · adults undergoing non‐cardiac surgery under general anaesthesia (to include: low‐risk, medium‐risk, and high‐risk surgeries)
It is very uncertain whether perioperative beta‐blockers changes ventricular arrhythmias (within 30 days) compared with placebo or standard care (very low certainty).
1 finding from 1 review
Atrial fibrillation or atrial flutter, or both (within 30 days) · adults undergoing non‐cardiac surgery under general anaesthesia (to include: low‐risk, medium‐risk, and high‐risk surgeries)
Perioperative beta‐blockers may leads to lower atrial fibrillation or atrial flutter, or both (within 30 days) compared with placebo or standard care (low certainty).
1 finding from 1 review
Bradycardia · adults undergoing non‐cardiac surgery under general anaesthesia (to include: low‐risk, medium‐risk, and high‐risk surgeries)
Perioperative beta‐blockers may leads to higher bradycardia (within 30 days; as defined by study authors, minimum… compared with placebo or standard care (low certainty).
1 finding from 1 review
Hypotension · adults undergoing non‐cardiac surgery under general anaesthesia (to include: low‐risk, medium‐risk, and high‐risk surgeries)
Perioperative beta‐blockers probably leads to higher hypotension (within 30 days; as defined by study authors, minimum… compared with placebo or standard care (moderate certainty).
1 finding from 1 review
Overall local/injection site adverse events at 15‐day · 10‐ to 26‐year‐old males
Three doses HPV vaccine leads to higher overall local/injection site adverse events at 15‐day compared with control (high certainty).
1 finding from 1 review
Overall systemic events and general symptoms · 10‐ to 26‐year‐old males
Three doses HPV vaccine showed no clear difference in overall systemic events and general symptoms at 15‐day compared with control (moderate certainty).
1 finding from 1 review
Overall local/injection site adverse events at 15‐day · 9‐ to 26‐year‐old females and males
Nonavalent HPV vaccine leads to higher overall local/injection site adverse events at 15‐day compared with quadrivalent HPV vaccine (high certainty).
1 finding from 1 review
Overall systemic events and general symptoms · 9‐ to 26‐year‐old females and males
Nonavalent HPV vaccine showed no clear difference in overall systemic events and general symptoms at 15‐day compared with quadrivalent HPV vaccine (moderate certainty).
1 finding from 1 review
Number of immediate (less than 24 hours) and delayed (24 hours to 10 days) postoperative bleeding episodes requiring intervention · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions
The review found no eligible studies for this question.
1 finding from 1 review
Length of stay (inpatients only) · dysphagia in acute and subacute stroke
1 finding from 1 review
All‐cause mortality (within 90 days)
Gelatins showed no clear difference in all‐cause mortality (within 90 days) compared with crystalloid (low certainty).
1 finding from 1 review
All‐cause mortality (within 30 days)
Gelatins showed no clear difference in all‐cause mortality (within 30 days) compared with crystalloid (low certainty).
1 finding from 1 review
All‐cause mortality (within 90 days)
Albumin and fresh frozen plasma showed no clear difference in all‐cause mortality (within 90 days) compared with crystalloid (moderate certainty).
1 finding from 1 review
All‐cause mortality (at 90 days)
Starches showed no clear difference in all‐cause mortality (at 90 days) compared with crystalloid (moderate certainty).
1 finding from 1 review
All‐cause mortality (within 30 days)
Albumin and fresh frozen plasma showed no clear difference in all‐cause mortality (within 30 days) compared with crystalloid (moderate certainty).
1 finding from 1 review
All‐cause mortality (within 30 days)
Starches showed no clear difference in all‐cause mortality (within 30 days) compared with crystalloid (moderate certainty).
1 finding from 1 review
All‐cause mortality (within 90 days and within 30 days)
Dextrans showed no clear difference in all‐cause mortality (within 90 days and within 30 days) compared with crystalloid (moderate certainty).
1 finding from 1 review
All‐cause mortality at 30 days · people with cirrhotic portal hypertension
It is very uncertain whether surgical portosystemic shunts changes all‐cause mortality at 30 days compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
1 finding from 1 review
Number of participants with Variceal rebleeding episodes at 30 days · people with cirrhotic portal hypertension
It is very uncertain whether surgical portosystemic shunts changes number of participants with Variceal rebleeding episodes at 30 days compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · patients with suspected appendicitis
3 findings from 1 review